<DOC>
	<DOCNO>NCT02502123</DOCNO>
	<brief_summary>This study prospectively assess long term heath relate quality life chronic migraine patient currently treat OnabotulinumtoxinA injection ( BOTOX® ) standard care .</brief_summary>
	<brief_title>Patient Reported Outcomes Patients With Chronic Migraine Treated With BOTOX®</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Patients chronic migraine eligible receive treatment onabotulinumtoxinA ( BOTOX® ) standard care . Diagnosis hemiplegic migraine , basilar migraine , ophthalmoplegic migraine migrainous infarction , chronic tensiontype headache , hypnic headache , hemicrania continua new daily persistent headache . Patient currently take plan take opioidcontaining product , barbiturate combination acute headache pain condition . Treatment botulinum toxin product condition within 3 month screen visit . Diagnosis myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis significant disease might interfere neuromuscular function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>